Who Qualifies for Retatrutide? Early Access, Trials, and After Approval
By The RX Index Editorial Team · Last verified October 17, 2026
Who qualifies for retatrutide right now? Access is limited. It isn't FDA-approved, so there's no normal prescription. Trials set their own rules. Lilly's expanded access requires adults to meet all five criteria, including body mass index (BMI) 35+ despite taking and tolerating the highest available weight-management dose, plus two serious weight-related complications under care. Meeting the rules doesn't guarantee access.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Read how we evaluate.
What changes your answer: your treatment history at the highest available dose of a weight medicine, whether two serious weight-related conditions are being treated, and whether a trial is within reach. If retatrutide is approved, its label will set the approved uses. That label doesn't exist yet.
Below: a table that shows which door is yours, the five rules in plain English, and one trade-off to know before you start or stop any GLP-1.
RX Index Decision Verdict: There's no normal prescription path yet. The win is knowing which door is yours, so you don't spend months waiting on the wrong one.
- Best for: adults with a BMI of 35 or more whose response to the highest available dose of an approved weight-management medicine wasn't enough, and who have two serious weight-related conditions under treatment.
- Not ideal for: anyone hoping for a normal prescription, a waitlist, or a faster way to "more" weight loss.
- The factor that matters most: your full medical record, and a doctor willing to make the request.
Which retatrutide door fits you?
There are three ways people talk about "qualifying" for retatrutide, and each has different rules. Today, only two are open: Lilly's expanded access program and a small number of clinical trials. A normal prescription doesn't exist until the FDA approves the drug.
| Door | Who qualifies, in plain English | Who decides | Open on Oct 17, 2026? | Cost to you | Jump to |
|---|---|---|---|---|---|
| 1. Lilly early access (expanded access) | Adults 18+ with BMI 35+ despite taking and tolerating the highest available dose of a weight medicine, 2+ serious weight-related conditions under treatment, no workable trial, and all options (including surgery) discussed | Your treating doctor asks; Lilly reviews; FDA and an ethics board also sign off | Yes, but narrow | Lilly says the drug is free; visits, tests, and travel may not be | The five rules |
| 2. A clinical trial | Whatever that one study requires. Our registry search found one recruiting Lilly study, for fatty liver disease | The study team, at screening | Very limited | Ask the study site | Trial rules |
| 3. A normal prescription | Not set yet. Any FDA-approved label would set the approved uses | FDA, then your prescriber | No | No price announced | After approval |
| Not a door: "reta" sold online | Not lawful medical access | — | — | Unknown contents | Prescription and compounding |
Sources: Lilly Medical (last reviewed Aug 26, 2026), NCT07629401, Lilly's SYNERGY-Outcomes page, and FDA. Checked October 17, 2026.
Who qualifies for retatrutide early access?
Lilly's expanded access program lets a treating doctor ask for retatrutide for one adult patient before FDA approval. The patient must meet all five posted rules, and anyone with a medical reason not to take retatrutide is excluded. Meeting the rules makes someone eligible to be considered — Lilly still reviews every request one by one.
"Expanded access" is the FDA's name for getting an unapproved drug outside a clinical trial. You'll also hear "compassionate use." "Early access" is the news-headline version. On this page they all mean this one Lilly program, listed publicly as NCT07629401.
| Rule (Lilly's wording, shortened) | What it means in plain English | What trips people up | What your doctor writes down |
|---|---|---|---|
| 1. Age 18 or older | Adults only | Age alone qualifies nobody | Your age |
| 2. "Refractory obesity": BMI 35+ despite sticking with and tolerating the highest available dose of a chronic weight-management medicine | You took the top dose as prescribed, handled it, and your BMI is still 35 or more | "I want something stronger" isn't the same thing. Neither is "the highest dose I could handle" if that's below the top dose | Current BMI and date, medicine, dose history, how long, side effects, results |
| 3. Two or more serious or life-threatening weight-related conditions, being treated right now | At least two serious health problems tied to your weight, with standard care underway | Two diagnoses on a chart aren't automatically two serious conditions under current treatment | Each condition, how serious, current treatment, who treats it |
| 4. Can't join a retatrutide or similar trial — because you don't fit its rules or there's no enrolling site you can reasonably reach | A trial isn't a real option for you | Many people think this only means "medically ineligible." No reachable enrolling site counts too | Trials checked, dates, and why each doesn't work |
| 5. All standard options, including weight-loss surgery, discussed through shared decision-making | You and your doctor talked through everything else, surgery included | It's a conversation, not a requirement to have surgery | What you discussed and the plan you chose |
Source: Lilly Medical and NCT07629401, checked October 17, 2026.
BMI means body mass index — a number made from your height and weight. Refractory obesity means obesity that hasn't come down enough despite the treatment described in rule 2. The public rules don't set a minimum time on treatment, a weight-loss cutoff, or a list of conditions that count automatically. We won't invent one.
Some news stories listed four rules. The official record lists five. If your doctor is working from a news article, hand them the record instead.
Does "highest available dose" mean the highest dose I can handle?
No. The rule says "adherence to and tolerance of" the highest available dose. That's stricter than "the highest dose I could tolerate." Some news reports said "highest approved dose," but Lilly's own text says available.
If side effects kept you on a lower dose, don't change anything to fit a checklist. Ask your doctor to raise your exact history with Lilly. Lilly decides how it reads your record.
What counts as a "serious" condition?
Lilly doesn't publish a list. That's a decision for your doctor and Lilly. A diagnosis like sleep apnea or high blood pressure doesn't, by itself, prove the condition meets this program's bar.
Bring records that show how serious each condition is and how it's being treated. "Standard care" just means the usual treatment for that condition.
Do I have to have weight-loss surgery first?
No. The rule is that you've discussed surgery and the other standard options with your doctor. That's called shared decision-making: you go over the choices together and pick a plan. You don't have to have surgery or agree to it.
What if there's no trial near me?
That can count. Rule 4 says a lack of a "reasonably accessible enrolling site" is one way a trial isn't workable. Your doctor still has to check and write down which trials were looked at and why each doesn't fit.
Being far from a site doesn't settle the other four rules on its own.
The honest truth is that wanting more weight loss isn't enough to meet these rules. That's not a dead end. If you're also looking at medicines you can start now, the right GLP-1 path depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the paths and providers that fit — free, about 2 minutes, no signup. It doesn't apply for retatrutide or check your plan's actual coverage. Compounded medicines are not FDA-approved.
Prepare your retatrutide questions for your doctor
You don't need every answer before booking a visit. This check walks through Lilly's five rules one at a time and turns your answers into a list for your doctor. It can't tell you that you qualify — your doctor and Lilly have to review your medical history, and FDA and ethics-board steps still apply.
Use the check below or bring the blank questions sheet to your visit.
If any of the clinician-first situations below apply to you, choose "Start with my care team" and use the blank sheet.
This check organizes what you know and what you may want to ask your doctor. It does not determine eligibility or replace a review by your doctor and Lilly.
We don't save or send your answers. They clear when you refresh or reset. Printing creates a copy you control.
Choose how to prepare
Retatrutide expanded access — questions for my doctor
Reader answers are self-reported and unverified. This is a conversation aid.
The five public requirements
- Age 18 or older.
- BMI 35+ and highest available dose taken as prescribed and tolerated.
- Two or more serious weight-related conditions under current care.
- No workable retatrutide or similar trial.
- All standard options, including surgery, discussed.
The program excludes a medical contraindication to retatrutide — a medical reason not to use it. This worksheet cannot check that. Your doctor and Lilly review it.
Write-in lines for the visit
- Current BMI and date: ______________________________________________
- Medicine, highest dose reached, dates, how I responded: _______________
- Taking it as prescribed and side effects: _____________________________
- Conditions, seriousness, current treatment, who treats them: __________
- Trials checked, dates, and why each doesn't work: ____________________
- Other options discussed, including surgery: __________________________
- Who on my care team would manage the request: _______________________
- Costs to ask about (visits, tests, ethics review, travel): ______________
Program record and physician contact
NCT07629401 — official program record
Lilly Answers Center: 1-800-LillyRx (1-800-545-5979). The treating doctor makes the request.
Lilly supplies the product at no cost. Visits, tests, ethics review, monitoring, and travel are separate cost questions. Lilly does not ship the drug directly to patients.
Physician responsibilities described in the public sources
- Agreement and FDA request as sponsor.
- IRB review and patient consent.
- Secure, temperature-controlled storage and dispensing.
- Returns or destruction, adverse-event reports, and final reports.
Primary sources
- Lilly Medical: retatrutide expanded access (last reviewed August 26, 2026)
- NCT07629401 (updated August 6, 2026)
- FDA physician instructions
- FDA expanded-access information for patients
- CDC BMI formula
Fixed message to my doctor
Subject: Could we review retatrutide expanded access? I read about Lilly's retatrutide expanded access program (registry record NCT07629401). Could we review whether its five published requirements might apply to me? I'd like to go over my current BMI, my treatment history and how I've responded, the conditions I'm being treated for, any trial options, and the other treatments we've discussed, including surgery. I understand a checklist isn't approval. Could your practice manage an investigational drug request and the monitoring it needs, or help me find a team that can? Before we start, I'd also like to understand any costs for visits, tests, ethics review, or travel. What should our plan be while this is considered?
Public sources checked October 17, 2026. Answers are unverified. This is a conversation aid, not an application or a clinical decision.
A quick example (made up, to show how it works): Say you're 52, 5'6", and 230 pounds. That's a BMI of about 37.1. You've been on the highest available dose of Zepbound for nine months, you take it as prescribed, and your weight stalled. You use a CPAP machine for sleep apnea and take two blood pressure pills. No retatrutide trial near you is enrolling, and your doctor walked you through surgery as an option. That's a useful history to bring — not proof you meet all five rules. Your doctor still has to judge whether both conditions meet the "serious" bar and whether a similar trial is workable. Nine months is part of the example, not a program minimum.
How can I check my BMI?
BMI is your weight in pounds divided by your height in inches squared, times 703 (CDC formula). It's a screening number, not a diagnosis. Use a recent measurement from your doctor's office if you have one.
Here's where the common cutoffs land. BMI 35 is the early-access floor; 27 and 30 are common entry cutoffs in weight-loss trials.
| Height | BMI 27 | BMI 30 | BMI 35 (early access floor) |
|---|---|---|---|
| 5'0" | 139 lb | 154 lb | 180 lb |
| 5'2" | 148 lb | 165 lb | 192 lb |
| 5'4" | 158 lb | 175 lb | 204 lb |
| 5'6" | 168 lb | 186 lb | 217 lb |
| 5'8" | 178 lb | 198 lb | 231 lb |
| 5'10" | 189 lb | 210 lb | 244 lb |
| 6'0" | 200 lb | 222 lb | 259 lb |
| 6'2" | 211 lb | 234 lb | 273 lb |
| 6'4" | 222 lb | 247 lb | 288 lb |
Weights rounded up to the nearest pound, calculated with the CDC formula.
A message you can send your doctor
Copy this into your patient portal or bring it to your visit:
Subject: Could we review retatrutide expanded access? I read about Lilly's retatrutide expanded access program (registry record NCT07629401). Could we review whether its five published requirements might apply to me? I'd like to go over my current BMI, my treatment history and how I've responded, the conditions I'm being treated for, any trial options, and the other treatments we've discussed, including surgery. I understand a checklist isn't approval. Could your practice manage an investigational drug request and the monitoring it needs, or help me find a team that can? Before we start, I'd also like to understand any costs for visits, tests, ethics review, or travel. What should our plan be while this is considered?
This is a conversation starter we wrote. It isn't a Lilly form, an FDA filing, or a statement that you meet any rule.
Blank lines for the visit:
- Current BMI and date: ______________________
- Medicine, highest dose reached, dates, how I responded: ______________________
- Taking it as prescribed and side effects: ______________________
- Conditions, how serious, current treatment, who treats them: ______________________
- Trials checked, dates, why each doesn't work: ______________________
- Other options discussed, including surgery: ______________________
- Who on my care team would manage the request: ______________________
- Costs to ask about (visits, tests, ethics review, travel): ______________________
Is Lilly's early access program real?
Yes. Lilly posted the program to the federal trial registry on June 5, 2026, and on August 3, 2026, told reporters it was reviewing requests from health care providers. It's a case-by-case exception for a small group of patients, not a launch or a waitlist.
| Date | What happened | Source |
|---|---|---|
| April 2026 request; reported June 23 | STAT reported that a request for one 79-year-old patient led to compassionate access. That's reporting on one case, not the current rules. | STAT |
| June 5, 2026 | Lilly's expanded access record posted publicly | NCT07629401 |
| August 3, 2026 | Lilly confirms it's reviewing physician requests | STAT |
| August 6, 2026 | Last update posted to the record | NCT07629401 |
| August 26, 2026 | Lilly's professional page on the program last reviewed | Lilly Medical |
You may run into what looks like a contradiction. Lilly's public retatrutide FAQ (updated September 2026) still says retatrutide is legally available only through Lilly's clinical trials. Lilly's professional page and the registry record describe the expanded access route. We show both so you're not caught off guard. For this program, the professional page and the record are the specific documents.
The public program documents don't give a total number of accepted requests or anyone's odds.
How does your doctor apply for retatrutide early access?
Your treating doctor — not you — starts by calling the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). If the first information fits, Lilly sends a detailed intake form and reviews the case. If Lilly agrees, your doctor files with the FDA, gets an ethics board's approval, and you sign a consent form before the first dose.
Lilly's record says patients and caregivers should go to their own doctor, not call Lilly. So your first move is booking the visit.
| Step | Who acts | What happens |
|---|---|---|
| 1. Talk it through | You + your treating doctor | Review your record, other options, trials, and risks |
| 2. First contact | Your doctor | Calls 1-800-LillyRx (1-800-545-5979) |
| 3. Detailed intake | Your doctor + Lilly | If the first information fits, Lilly sends an intake form and reviews the case |
| 4. Paperwork | Your doctor | Signs a letter of agreement with Lilly and files an FDA request as the "sponsor" (for one patient, usually Form FDA 3926) |
| 5. Ethics review | Your doctor + an IRB | An IRB (institutional review board — an ethics panel that protects patients) approves the plan |
| 6. Consent | You | You sign a form explaining the drug isn't approved and its risks aren't fully known |
| 7. Supply and follow-up | Your doctor's office | Receives, stores at the right temperature, and hands out the medicine; reports side effects and a final report |
Sources: Lilly Medical; FDA physician instructions. Checked October 17, 2026.
Lilly doesn't ship the drug to patients. It goes to your doctor.
Lilly is the first gate, not the only one
Think of renting an apartment. The landlord has to agree to hand over the keys, but the city's safety rules still apply.
Lilly is the landlord here. FDA says it allows over 99% of the single-patient expanded access requests it receives to proceed — but that figure covers many drugs and only requests that reach FDA. It isn't your chance of getting retatrutide. No law makes a company supply its drug, so without Lilly's yes, nothing moves.
How long does it take?
Lilly's expanded access policy says it responds within five business days after it has the request and the medical information it needs. A response isn't an approval. For a non-emergency single-patient request, FDA says treatment may begin 30 days after FDA receives it, or sooner if FDA allows, unless FDA places the request on hold. IRB approval and consent must come first.
Neither clock is a promised total wait from your first call. In August, STAT reported that some doctors had sent requests without a reply. The program documents give no average end-to-end time.
Can my doctor really take this on?
Your doctor needs the setup to manage an investigational medicine, not just write a prescription. Under Lilly's terms, your doctor becomes responsible for storage, handing out the drug, returns, an ethics board, and safety reports. A busy primary-care office may not be built for that.
Ask whether a hospital-based obesity clinic or a practice that runs research could help. If your doctor can't take it on, ask who in your area can.
Can a telehealth doctor apply?
The record says the request comes from the treating physician, and that doctor has to take responsibility for your care under the program. Whether an online practice can handle storage, the ethics board, and reporting is a question for that practice — and Lilly decides.
How much does retatrutide early access cost?
Lilly says it provides the drug itself at no cost through this program. Everything around the drug — visits, lab tests, monitoring, ethics board review, and travel — is a separate question. FDA warns that costs tied to expanded access are often not covered by insurance, so ask for an estimate before you start.
Think of a free concert ticket. The ticket is free. Parking and gas still cost you.
| Cost | What the sources say | What to ask |
|---|---|---|
| The drug | Lilly: provides products at no cost through the program | Is anything for handling billed separately? |
| Doctor visits | No set price published | What's due for the first visit, and what repeats? |
| Lab tests and monitoring | No set price published; FDA warns related services are often not covered | Which tests, who bills them, does my plan pay? |
| Ethics board (IRB) review | FDA says you may have to pay, depending on the board | Will any review fee be passed to me? |
| Travel | No travel-payment terms in the program documents we checked | Where do I go, and how often? |
| Total for a year | Can't be calculated from public information | Get a written estimate. An unknown fee isn't a $0 fee. |
Sources: Lilly Medical; FDA, information for patients.
Federal rules back this up: a company needs FDA's written permission to charge for an investigational drug in a single-patient request and may recover only the permitted direct costs (21 CFR 312.8). Lilly says it isn't charging for the drug.
Say your doctor's office confirms the drug is free, but hasn't priced the visits or labs yet. Your estimate isn't $0. It's "not finished." One question gets you the real picture: "What could I owe if Lilly says no, and what costs start only if treatment goes ahead?"
Can you qualify through a retatrutide clinical trial?
Trial rules belong to one study at a time, not to retatrutide as a whole. Our October 17, 2026, ClinicalTrials.gov search found one Lilly retatrutide study listed as recruiting: SYNERGY-Outcomes, a roughly 4.5-year study for adults with high-risk fatty liver disease. The TRIUMPH studies shown below are closed to new people.
This table shows the studies' main screening rules and whether they're open to new people. The rules describe who could join, not each participant's health history or treatment assignment. These are selected requirements; the study team checks the full protocol.
| Study | Who could join (main entry rules) | Examples of who was kept out | Status (last update posted) | Treatment assignments |
|---|---|---|---|---|
| SYNERGY-Outcomes (NCT07165028) | Adults 18+ with fatty liver disease (MASLD) at high risk, shown by MRI liver fat and non-invasive scarring tests; BMI 25+ | Other liver diseases; liver-history exclusions differ between the sources below; losing more than 11 lb in the 3 months before screening; A1C above 10%; type 1 diabetes | Recruiting (Oct 8, 2026); Lilly also says Enrolling | Retatrutide or placebo in one part; tirzepatide or placebo in another |
| TRIUMPH-9 | Adults 18+ with BMI 30+, or 27+ with high blood pressure, abnormal cholesterol, sleep apnea, or heart disease; at least one failed diet attempt | Type 1 or type 2 diabetes; personal or family history of medullary thyroid cancer or MEN 2; pancreatitis; weight-loss drugs in the last 90 days; prior or planned weight-loss surgery | Active, not recruiting (Jun 9, 2026) | Retatrutide in all groups; no placebo |
| TRIUMPH-8 | Adults 18+; same BMI, condition, and failed-diet rules as TRIUMPH-9 | Same listed exclusions as TRIUMPH-9 | Active, not recruiting (Apr 17, 2026) | Retatrutide or placebo |
| TRIUMPH-7 | Adults 18+ with BMI 27+, pain mainly centered in the low back and limited to the low back or upper legs, and at least one failed diet attempt | Any type of diabetes; weight-loss drugs in the last 90 days; prior or planned weight-loss surgery | Active, not recruiting (Sep 25, 2026) | Retatrutide or placebo |
| TRIUMPH-3 | Adults 18+ with BMI 35+, past heart attack, stroke, or symptomatic artery disease in the legs, and at least one failed diet attempt | Type 1 diabetes; medullary thyroid cancer or MEN 2 history; pancreatitis; weight-loss drugs in the last 90 days | Completed (Jul 30, 2026) | Retatrutide or placebo |
| TRIUMPH-2 | Adults 18+ with BMI 27+, type 2 diabetes on stable treatment for at least 90 days, and at least one failed diet attempt | — | Completed (Jul 30, 2026) | Retatrutide or placebo |
| TRIUMPH-Outcomes | Adults 45+ with BMI 27+ and established cardiovascular disease from artery plaque and/or chronic kidney disease that meets the study's test limits | — | Active, not recruiting (Oct 8, 2026) | Retatrutide or placebo |
| NCT07467447 | Adults 18–75 with BMI 30–50, or BMI 27 to below 30 with a listed weight-related condition; diabetes is excluded | Weight-loss drugs in the last 3 months | Recruiting (Mar 12, 2026). Sponsor listed as Hudson Biotech, one site in Shenzhen, China; Lilly involvement not confirmed | Retatrutide or placebo listed |
| Expanded access (NCT07629401) | Adults who meet all five rules above | A medical reason not to take retatrutide | Available (Aug 6, 2026) | Individual retatrutide treatment, not a placebo trial |
Statuses are for the whole study, not any one site. "Active, not recruiting" and "completed enrollment" both mean no new people. Registry dates are when an update was posted; we checked the records October 17, 2026. A dash means this table doesn't summarize the exclusions, not that none apply.
For SYNERGY, the registry requires all three screening findings: liver fat of at least 8%, an ELF score from 9 through 10.8, and a VCTE liver-stiffness result of at least 10 but below 20 kPa. The study team interprets these liver-fat and liver-scarring tests. BMI alone isn't enough (NCT07165028).
The liver-history exclusions also differ in the public sources. Lilly's study page lists past cirrhosis, including a past biopsy diagnosis. The registry uses "prior decompensated liver disease" and lists serious complications. Those aren't the same wording. Ask the study team how it applies the rule to your history.
To ask about SYNERGY-Outcomes, use Lilly's official study page. It says to expect about 30 visits over about 4.5 years. It lists a study nurse line at 1-844-200-7254 and the Lilly Trial Information Center at 1-877-285-4559. Three questions worth asking: Is a site near me screening this week? Which treatments could I be assigned? What records do you need?
To look for newly posted studies, search the official retatrutide records. Not every result is a Lilly study or a real path for you. Our retatrutide trial tracker has the full register.
Does taking a GLP-1 now help or hurt my chances?
It can cut both ways, which almost nobody explains. Lilly's early access rule 2 is about your response to the highest available dose of an approved weight medicine, so treatment history is part of that door. But several retatrutide trials, including TRIUMPH-7 and TRIUMPH-9, excluded anyone who took weight-loss medicine in the 90 days before screening.
Those are each study's own rules, not a universal waiting period. This is a choice for you and your prescriber. Never start, stop, or change a medicine just to fit a door. If you're on tirzepatide now, see switching from tirzepatide to retatrutide.
Does "recruiting" mean there's a spot for me?
No. A recruiting status means the study as a whole is taking people. It doesn't mean you meet the rules or that a site near you is screening now. Call the site before you book travel or change anything.
Will joining a trial get me retatrutide?
Not guaranteed. Many studies include a placebo — a look-alike shot without the drug — and SYNERGY-Outcomes can assign retatrutide, tirzepatide, or placebo. Ask which assignments are possible in the exact part of the study you'd join.
For the study details, see retatrutide for fatty liver.
For the trial results, see what retatrutide has shown for sleep apnea.
For the knee-specific evidence, see what retatrutide has shown for knee osteoarthritis.
Who will qualify for retatrutide after approval?
Nobody knows yet, because retatrutide has no FDA-approved label. Lilly said on July 23, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027, and that its data can support submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea. Filing is a request, not an approval.
The study table above shows which groups the studies were designed to enroll. For example, TRIUMPH-8 and TRIUMPH-9 used BMI 30+, or 27+ with a listed weight-related condition. Other studies focused on type 2 diabetes, heart disease, kidney disease, knee arthritis, back pain, or fatty liver disease.
Trial rules are not the future label. An FDA-approved label sets the approved uses and safety restrictions. For comparison only: Zepbound, an approved drug from the same company, is approved for weight management in adults with obesity, or adults with overweight and at least one weight-related condition, along with a reduced-calorie diet and increased physical activity (Zepbound prescribing information). Retatrutide's label could look different.
A trial exclusion also isn't automatically a future "can't take it" rule. People were kept out of studies for many reasons, including keeping the results clean. And early access is different again: Lilly says that program ends once the drug is approved and sold.
For the timeline math, see retatrutide availability and how FDA approves obesity drugs.
Should anyone talk to a clinician before planning on retatrutide?
Yes. Some people should get medical advice before planning around any GLP-1-type medicine, retatrutide included. This list is about being careful, not a formal list of who can never take it.
Start with your own clinician if you are:
- Under 18
- Pregnant, planning a pregnancy, or breastfeeding (GLP-1s, pregnancy, and birth control)
- Living with type 1 diabetes
- Living with or recovering from an eating disorder
- Someone with a personal or family history of medullary thyroid cancer or MEN 2, or a history of pancreatitis — retatrutide trials commonly kept these people out (GLP-1 hard contraindications)
- Someone who's been told a weight medicine may be unsafe for you
If any of these fit, a provider match or an online check isn't medical clearance.
Will insurance or Medicare cover retatrutide?
There's no FDA-approved retatrutide prescription for a plan to cover. For expanded access, Lilly supplies the drug at no cost; ask your plan separately about visits, tests, and monitoring. FDA says related costs are often not covered — it doesn't say coverage is impossible (FDA patient information).
Retatrutide isn't on Medicare's GLP-1 Bridge list, which runs July 1, 2026, through December 31, 2027, and names only Foundayo, Wegovy (injection and tablets), and Zepbound KwikPen (CMS, checked October 17, 2026).
That product list doesn't decide which other medical services your plan might cover. See insurance and costs beyond the medicine and Medicare and retatrutide-related care costs for those separate questions.
If retatrutide is approved, coverage and any prior authorization would depend on your plan and the use being covered. Prior authorization is a permission slip from your insurer before it pays. For what might happen later, see whether retatrutide will be covered by the CMS BALANCE model and our retatrutide cost predictions.
What if you don't qualify for retatrutide yet?
Not fitting Lilly's rules doesn't mean you're out of options. FDA-approved medicines are available to discuss with a clinician now, and using one doesn't stop you from asking about retatrutide later. The right next step depends on where you are.
No web page, including this one, can tell you whether you'll get retatrutide. Your doctor and Lilly decide early access; a study team decides trials. Here's how to use the waiting time well.
| If this is you | Your next step |
|---|---|
| BMI under 35 and never tried a GLP-1 | Ask a licensed prescriber whether an approved medicine fits your health. Waiting for an unannounced launch date isn't a treatment plan. |
| On the top dose and stalled, BMI under 35 | Talk with your prescriber about what's next: best GLP-1 after Zepbound, after Wegovy, and our GLP-1 non-responder research. |
| Couldn't handle a higher dose | Review your real history with your prescriber. Don't change treatment to fit this page. |
| You might fit all five rules | Print your questions and book a visit with the doctor who treats your weight. |
| Don't know your BMI or how serious your conditions are | Use the blank checklist and ask for the missing measurements. |
| On Medicare | Start with your plan and our Medicare GLP-1 Bridge eligibility guide. |
| On Medicaid | Start with your plan and our guide to what GLP-1s Medicaid covers. Ro says Medicaid patients cannot use its treatment program (Ro). |
| Weighing surgery | See GLP-1 vs. bariatric surgery. |
| In the "talk to a clinician first" group above | Start with your clinician. No provider match is medical clearance. |
If you have a job-based or Marketplace plan and want to see whether an FDA-approved option is covered before you assume it's a no, Ro offers a free coverage check. It looks at the Ozempic, Wegovy, and Zepbound pens, asks for your name, insurance-card details, and eligibility information, and emails you a report. It doesn't prescribe anything, submit a treatment request, or promise coverage, and it can't check the Zepbound KwikPen, Foundayo pill, or Wegovy pill right now (Ro's checker, checked October 17, 2026). Medicare, Medicaid, and TRICARE members should start with their own plan.
The free check is separate from Ro's paid treatment program. If you later join and a clinician prescribes a supported medicine, Ro's insurance team can handle prior-authorization paperwork. Your insurer can still say no, and insurance doesn't cover the membership fee (Ro insurance).
Check coverage for approved GLP-1 pens with Ro
If your plan won't pay or you don't have insurance, the question becomes the whole receipt, not the sticker price. Ro's membership is $39 for the first month (Ro refunds it if you're not eligible for GLP-1s), then $74 to $149 a month depending on your plan. After that first month, the $74 monthly equivalent requires $888 up front for the next 12 months of membership. The month-to-month plan is $149 a month after the first month. Medication is a separate charge (Ro pricing, checked October 17, 2026).
Ro lists the Wegovy pill and Foundayo pill starting at $149 a month; prices at higher prescribed strengths reach $299, with some Foundayo prices tied to offers. Zepbound KwikPen starts at $299 for four weekly doses — a 28-day supply. Ro lists $399 for the next strength and $449 with an offer for higher strengths. Lilly's $449 offer requires refill purchases within 45 days of the previous delivery; without that offer, its listed higher-strength prices are $499 or $699. Lilly's current self-pay savings-card terms end December 31, 2026; don't treat an offer price as a year-long price lock. These are medication charges on top of membership, and taxes or other fees may apply (Ro pricing; Lilly's current price and offer terms).
Ro says its cash prices match LillyDirect, NovoCare, and TrumpRx. That last part is Ro's claim, not a full comparison we ran across those programs.
Ro automatically renews the plan you choose. Its membership terms make paid membership fees non-refundable once treatment is prescribed; don't assume unused prepaid months will be refunded. Cancel at least 48 hours before renewal to stop the next charge. Your care continues through the paid period. Medication refund rules are separate. The terms include 24 medical consultations a year, charge $15 for each one after that, and allow separate charges for extra lab tests.
Before you choose cash pay: Ro says Medicaid and some other government-funded plans make patients ineligible for its treatment program. Medicare, Medicare supplement, and TRICARE members may be eligible for certain cash-pay options; federal employee health benefits (FEHB) members can use its insurance concierge. Confirm the option that applies to your plan (Ro insurance).
Can you get retatrutide by prescription or from a compounding pharmacy?
No to both. There's no FDA-approved retatrutide, so there's nothing for a normal prescription to fill. FDA states that retatrutide cannot be used in compounding under federal law and has warned telehealth companies, ingredient sellers, and outsourcing facilities over it.
Early access isn't a back door to an online seller, either. FDA also warns about products labeled "for research purposes" or "not for human consumption" that are sold to people anyway — their quality is unknown. Paying an online clinic doesn't secure Lilly's approval; the documented process starts with your treating doctor. More: compounded retatrutide and how to avoid fake GLP-1 medicines.
What early access doesn't mean
Early access isn't FDA approval, and it doesn't give you a launch date or a pharmacy price. For the separate product and shopping questions, see early access isn't a retatrutide pill, why expanded access isn't an online retatrutide order, and why it doesn't run through LillyDirect.
On August 12, 2026, Lilly announced six lawsuits against sellers it alleges illegally marketed retatrutide, including under "research use only" claims. Those are Lilly's allegations, not court findings. Our Lilly retatrutide lawsuits guide follows that separate story.
If you've used something labeled retatrutide and feel unwell, call your doctor. If someone collapses, has a seizure, has trouble breathing, or can't be woken up, call 911. For a suspected poisoning or an unknown product, call U.S. Poison Control at 1-800-222-1222 (Poison Control), and keep the label and packaging.
What we actually verified
We checked the program rules, trial records, and prices against Lilly's, FDA's, CMS's, ClinicalTrials.gov's, and Ro's own pages on October 17, 2026. Where two official sources disagree, we show both. We didn't contact Lilly, apply for the program, call study sites, or use any retatrutide product.
Checked October 17, 2026:
- Lilly Medical's expanded access page (last reviewed by Lilly August 26, 2026): five rules, exclusion, no-cost drug, physician duties, no direct shipping, program end
- NCT07629401 (last update posted August 6, 2026)
- Lilly's expanded access policy: five-business-day response, regulator approval before shipping, local Lilly office outside the U.S.
- FDA physician instructions: 30-day timing, Form FDA 3926, IRB and consent, the 99% figure
- FDA patient information and 21 CFR 312.8: possible care and review costs, limits on charging for the drug
- FDA's unapproved GLP-1 page (current as of October 1, 2026): compounding and "research use" warnings
- Lilly's SYNERGY-Outcomes page and registry criteria, status dates, and assignments for every study in the table; the filtered registry search returned SYNERGY-Outcomes and the separately sponsored Hudson study
- Lilly's retatrutide FAQ and July 23, 2026 filing plan
- CMS Medicare GLP-1 Bridge page (last modified August 6, 2026)
- Zepbound's prescribing information (revised August 2026): current weight-management indication; Lilly's price and offer terms: KwikPen supply period and refill-offer limits
- Ro's pricing, coverage checker, insurance page, and membership terms (last revised April 2, 2026) — published terms, not a checkout we completed or a coverage report we received
- CDC's BMI formula, every weight in the BMI table, and the worked example; Poison Control's emergency guidance
- The accessible openings of the two dated STAT reports below, for history only; Lilly's August 12 lawsuit announcement, as allegations rather than court findings
Source conflicts: Lilly's public FAQ says trials only; the program record and Lilly's professional page describe expanded access. For SYNERGY, Lilly's study page and the registry use different liver-history exclusion wording, explained above.
What we couldn't confirm: how many requests Lilly has approved; whether any one person will be accepted; total costs for visits, tests, and review; how long anyone receives the drug; whether a given trial site is screening this week; your insurer's answer; or what the future label will say.
Who qualifies for retatrutide: FAQ
Can I qualify if I'm just below the BMI cutoff?
Not for Lilly's early access — its rule is a BMI of 35 or higher, despite the highest available dose of a weight medicine. Trials set their own BMI rules, but you'd still need a study that's open and accepting people. Never change your weight or treatment to hit a number.
How do I get into a retatrutide trial, and why didn't anyone call me back?
Start from a specific study record and contact that study's listed team; a general sign-up doesn't mean a site is screening. Our October 17, 2026, registry search found one recruiting Lilly retatrutide study: the SYNERGY-Outcomes liver study. If you hear nothing, call the study nurse line on Lilly's study page and ask whether a site near you is screening this week.
Can I apply for early access myself or join a waitlist?
No. Your treating doctor makes the request by calling the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). There's no public sign-up or waitlist.
Does being on Wegovy, Zepbound, or Mounjaro rule me out?
Not for early access — rule 2 actually looks at how you did on the highest available dose of a weight medicine. Some trials, though, excluded weight-loss medicine used in the 90 days before screening. Don't stop or change a prescribed medicine without your prescriber and the study team.
What if I could only handle a lower dose?
Bring that history to your doctor. Lilly's wording says highest available dose, so a lower tolerated dose isn't an automatic match. Lilly decides how it reads your record.
Does type 2 diabetes make me qualify?
No. A diabetes diagnosis isn't one of the five rules, and some retatrutide studies excluded diabetes entirely while others studied it on purpose. The specific program or study sets the rules.
Is retatrutide early access free?
Lilly says it provides the drug at no cost. Visits, tests, monitoring, ethics board review, and travel aren't covered by that statement, and FDA warns related costs are often not covered by insurance. Ask for a written estimate first.
Does an "Available" status on the registry mean I'll be accepted?
No. It means the program exists and is taking requests. Each request still gets Lilly's individual review, plus FDA and ethics-board steps.
How long does it take?
Lilly says it responds within five business days after it has the request and required medical information. For a non-emergency FDA request, treatment may start 30 days after FDA receives it, or sooner if FDA allows, unless FDA places it on hold; IRB approval and consent must also be in place. Neither is a promised total wait.
Will I qualify for retatrutide after it's approved?
Unknown until there is an FDA-approved label. Lilly said on July 23, 2026, that it plans to submit in the first quarter of 2027. Several weight trials used a BMI of 30+, or 27+ with a weight-related condition, but trial rules aren't the label.
Can people outside the U.S. use these rules?
Don't assume so. The five rules are on the U.S. record. Outside the U.S., Lilly says doctors should contact their local Lilly office, and that country's regulator must approve first.
How long would I keep getting it?
The public program documents do not promise an individual treatment duration. Lilly says expanded access ends after potential FDA approval and commercial availability. Ask your doctor what follow-up and transition plan would apply to you.
Is online "reta" the same as Lilly's early access?
No. FDA says retatrutide can't be compounded under U.S. federal law, and a "research use" label isn't proof of real Lilly supply. Lilly's program ships only to the treating doctor.
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.
For the diabetes-specific explanation, see why type 2 diabetes alone doesn't qualify you.
Sources
Checked October 17, 2026. Dates in parentheses belong to the source.
- ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide, NCT07629401 (first posted June 5, 2026; last update posted August 6, 2026).
- Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed August 26, 2026).
- Eli Lilly — Expanded Access policy.
- FDA — For Physicians: How to Request Single Patient Expanded Access.
- FDA — Expanded Access: Information for Patients.
- eCFR — 21 CFR 312.8, Charging for investigational drugs.
- FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026).
- Eli Lilly — What to know about retatrutide (updated September 2026).
- Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026).
- Lilly Trials — SYNERGY-Outcomes.
- ClinicalTrials.gov — NCT07165028 (updated October 8, 2026), NCT07357415 (updated June 9, 2026), NCT07232719 (updated April 17, 2026), NCT07035093 (updated September 25, 2026), NCT05882045 and NCT05929079 (both updated July 30, 2026), NCT06383390 (updated October 8, 2026), NCT07467447 (updated March 12, 2026). These are last-update-posted dates.
- Eli Lilly — Zepbound prescribing information (revised August 2026).
- CMS — Medicare GLP-1 Bridge: Information for Providers (last modified August 6, 2026).
- CDC — Calculating BMI (June 18, 2024; formula only).
- Ro — Weight loss program pricing, GLP-1 insurance coverage checker, Insurance, and Terms of Use (terms last revised April 2, 2026).
- STAT — Original compassionate-access report (June 23, 2026) and Lilly's confirmation it was reviewing requests (August 3, 2026). Accessible openings checked; used for history only.
- National Capital Poison Center — Poison Control emergency guidance.
- Eli Lilly — Zepbound pricing and savings terms (current KwikPen price, supply, and offer conditions).
- Eli Lilly — Announcement of six retatrutide-related lawsuits (August 12, 2026; manufacturer allegations).
- FDA — Expanded Access: Information for Physicians.
Corrections: found an error? Email